...
首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Systemic Levels of Neuropeptide Y and Dipeptidyl Peptidase Activity in Patients With Ewing Sarcoma-Associations With Tumor Phenotype and Surviva
【24h】

Systemic Levels of Neuropeptide Y and Dipeptidyl Peptidase Activity in Patients With Ewing Sarcoma-Associations With Tumor Phenotype and Surviva

机译:患有肿瘤表型和Surviva的患者患者神经肽Y和二肽基肽酶活性的全身水平和二肽基肽酶活性

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Ewing sarcoma (ES) is driven by fusion of the Ewing sarcoma breakpoint region 1 gene (EWSR1) with an E26 transformation-specific (ETS) transcription factor (EWS-ETS), most often the Friend leukemia integration 1 transcription factor (FLI1). Neuropeptide Y (NPY) is an EWS-FLI1 transcriptional target; it is highly expressed in ES and exerts opposing effects, ranging from ES cell death to angiogenesis and cancer stem cell propagation. The functions of NPY are regulated by dipeptidyl peptidase IV (DPPIV), a hypoxia-inducible enzyme that cleaves the peptide and activates its growth-promoting actions. The objective of this study was to determine the clinically relevant functions of NPY by identifying the associations between patients’ ES phenotype and their NPY concentrations and DPP activity. METHODS: NPY concentrations and DPP activity were measured in serum samples from 223 patients with localized ES and 9 patients with metastatic ES provided by the Children’s Oncology Group. RESULTS: Serum NPY levels were elevated in ES patients compared with the levels in a healthy control group and an osteosarcoma patient population, and the ele-vated levels were independent of EWS-ETS translocation type. Significantly higher NPY concentrations were detected in patients with ES who had tumors of pelvic and bone origin. A similar trend was observed in patients with metastatic ES. There was no effect of NPY on survival in patients with localized ES. DPP activity in sera from patients with ES did not differ significantly from that in healthy controls and patients with osteosarcoma. However, high DPP levels were associated with improved survival. CONCLUSIONS:Systemic NPY levels are elevated in patients with ES, and these high levels are associated with unfavorable disease features. DPPIV in serum samples from patients with ES is derived from nontumor sources, and its high activity is correlated with improved survival
机译:背景:通过EWINGSARCOMA断点区域1基因(EWSR1)的融合,通过E26转化特异性(ERE)转录因子(EWS-ETS)来驱动EWING SARCOMA(EWSR1)驱动,大多数往往是朋友白血病集成1转录因子(FLI1 )。神经肽Y(NPY)是EWS-FLI1转录靶标;在ES中高度表达并施加相反的效果,从ES细胞死亡到血管生成和癌症干细胞繁殖。 NPY的功能由二肽基肽酶IV(DPPIV)调节,一种缺氧诱导酶,其切割肽并激活其生长促进作用。本研究的目的是通过识别患者ES表型和NPY浓度和DPP活性之间的关联来确定NPY的临床相关功能。方法:在223例局部ES和9例患有儿童肿瘤学院提供的转移性ES患者的血清样品中测量NPY浓度和DPP活性。结果:与健康对照组和骨肉瘤患者群体的水平相比,ES患者血清NPY水平升高,ELE-eRES-ets易位类型无关。在患有骨盆和骨源性肿瘤的患者中检测到显着较高的NPY浓度。转移性ES患者中观察到类似的趋势。本地化ES患者的生存率对生存没有NPE。 ES患者的血清中的DPP活性与骨肉瘤的健康对照和患者患者没有显着差异。然而,高DPP水平与改善的存活相关。结论:ES患者升高全身NPY水平,这些高水平与不利疾病的特征有关。来自ES患者的血清样品中的DPPIV来自Nontumor来源,其高活性与改善的存活率相关

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号